Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Care management intervention strategies
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

1 evidence topic · 2 sources

US HAEA Medical Advisory Board guidelines: on-demand medication access

“Effective treatment of HAE requires that all patients have rapid access to effective on-demand medications.” (opens the source at this quote in a new tab)